In this issue:
Biologics dose increase beyond label and pharmacy costs
Serum concentration after switch from infliximab to biosimilar CT-P13
Vedolizumab for UC
Concomitant 5-ASAs and biologic therapy in UC
Endoscopic healing with ustekinumab in CD
Panitumumab plus docetaxel/cisplatin/5-fluorouracil for gastric adenocarcinomas
Long-term golimumab for moderately to severely active UC
Ustekinumab effects on HR-QoL in CD
Ixekizumab and patient-reported outcomes in psoriatic arthritis
Please login below to download this issue (PDF)